YUMAB GmbH
  • Xing
  • Linkedin
  • Mail
  • Home
  • Company
    • Team
    • Network & Partners
    • Career
  • Contract Research
    • Discovery & Development of Antibodies from Target to Lead
      • Hit Discovery
      • Lead Engineering
      • Lead Development
    • Antibody Engineering
    • Antibody Humanization
    • Libraries
  • Partnering & Pipeline
    • Partnering, Collaboration & Pipeline
    • Project design & Licensing
  • Platform & Technologies
    • Library technologies
    • Antibody Discovery
    • Bioinformatics / YUcare
    • Antibody Engineering
    • Antibody Humanization
  • News & Events
    • News
    • Events
  • Contact
    • Contact
    • Directions
  • Search
  • Menu
Yumab-Slider-1

Fully Human Antibodies, Acceleration of Discovery & Development

Mission

CORAT's human antibody against COVID-19 ready for clinical trials
First batch of the SARS-CoV-2 blocking antibody COR-101 has been produced.
Read press release

Breaking News

Yumab BioStack

Individual Project Design, Fee for Service or Milestone-based

Contract Research, R&D Services

CORAT's human antibody against COVID-19 ready for clinical trials
First batch of the SARS-CoV-2 blocking antibody COR-101 has been produced.
Read press release

Breaking News

Yumab-Slider-3

Partnered R&D, Collaborations, Licensing

Pipeline & Partnering

CORAT's human antibody against COVID-19 ready for clinical trials
First batch of the SARS-CoV-2 blocking antibody COR-101 has been produced.
Read press release

Breaking News

Follow a manual added link

Breaking News

Innovation Award for CORAT’s COVID-19 antibody development
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for their efforts in the collaborative fast track development of therapeutic COVID-19 antibodies.

Read press release

YUMAB® – Company

YUMAB is a world leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies. The YUMAB® platform is based on almost 30 years of continuous research by its founders in antibody discovery and engineering. It combines state of the art and next generation technologies from target to lead under one roof. YUMAB offers individually designed projects and business solutions for small biotech start-ups up to large biopharma companies.

Read more 

News & Events

News & Events

Human antibody against COVID-19 ready for clinical trials
November 18, 2020

YUMAB spin-off CORAT Therapeutics today announced that the first major batch of its SARS-CoV-2 blocking antibody  COR-101 has been produced and is now available for clinical trials.
Read more

Innovation Award for CORAT Consortium
September 28, 2020
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for its efforts in the collaborative fast track development of therapeutic COVID-19 antibodies.
Read more

First SARS-CoV-2 neutralizing antibody discovered
May 07, 2020
YUMAB’s human SARS-CoV-2 antibody candidate exhibits a coronavirus neutralizing effect, as confirmed in preclinical tests with COVID-19 patient sera at the Helmholtz Center for Infection Research.
Read more

Coronavirus statement
March 20, 2020
YUMAB is committed to uphold its business activities during times of the coronavirus pandemic.
Read more

Proteins & Antibodies Congress
April 27-29, 2020
Meet Philipp Kuhn to discuss your needs in antibody development and engineering.
Read more

Enleofen enters joint development with Boehringer Ingelheim
January 09, 2020
YUMAB partner Enleofen joins forces with Boehringer Ingelheim to develop novel anti-IL-11 therapies for a range of fibrotic diseases.
Read more

microscope (1)

CRO / R&D Services

YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.

Read more 

connection

YUMAB® Platform, Partnering

YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.

Read more 

Bioinformatic Optimizations

3. September 2018/by admin

The Power of in vitro Selection

4. September 2018/by admin

Fully Human Therapeutic Antibodies

4. September 2018/by admin

Antibody Engineering

4. September 2018/by admin

Nature-derived Antibody Libraries

4. September 2018/by admin

YUMAB® – Versatile Platform Concept

4. September 2018/by admin

Contact

SEND US AN E-MAIL

0 + 1 = ?

YUMAB GMBH

Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany

Phone: (+49) 531-481170-0
Email: info@yumab.com

YUMAB Inc.

1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA

Phone: (+49) 531 481170-0
Email: info@yumab.com

YUMAB GmbH

Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany

Phone Yumab Phone: +49 531 481170-0
Fax Yumab Fax: +49-531 481170-17

More Information

Legal notice
Disclaimer, Data Privacy Statement
Terms and conditions
Sitemap

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings

How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Disclaimer